CommerceNet will be hosting its annual holiday party — complete with its traditional chocolate fountain — at our offices on University Avenue. Attendance is by invite only.
Want to attend?
Contact Keren Vanisi for more information.
All RSVPs are due by December 7.
This conference will cover keys issues, challenges and best practices for Collaborative Innovation in BioMedicine including:
CommerceNet’s own Dr. Jay M. Tenenbaum will give the luncheon keynote on June 23 at 12:30 pm.
Collaborating for Cures will bring together for the first time non-profit and industry leaders specifically focused on accelerating treatments and cures for brain and nervous system illnesses to promote the exchange of ideas, discuss funding opportunities and collaborative strategies.
Panelists and attendees will explore how new collaboration, innovative funding models, web-based collaborative infrastructures, and new partnership models are accelerating the development of treatments and cures for brain and nervous system illnesses.
CommerceNet’s own Dr. Jay M. Tenenbaum will give the keynote on May 11 from 8:30 - 9:00am and will also participate in the subsequent panel “Collaborative Research Infrastructure” from 9:00-10:30am.
The Melanoma Research Foundation, the largest private foundation devoted to the prevention and treatment of melanoma, will honor CommereNet’s own Dr. Jay M. Tenenbaum for his ongoing support. The “Legends for a Cure” gala will be held Thursday, May 14, 2009 at the San Francisco Film Centre in San Francisco. More details about the event and how to donate can be found at www.melanoma.org.
According to the Cambridge Health Institute (CHI), “the need for a more precise, predictive approach to medicine has never been greater, as we face two fundamental crises in the biotech and pharmaceutical industries. Healthcare costs are spiraling out of control in the face of near epidemics in diabetes and Alzheimer’s disease, an aging population, and soaring costs of new technology. Moreover, the pharmaceutical industry struggles as increasing costs, patient expirations, and the demise of the blockbuster model puts a premium on innovation and efficiency.
For 16 years, CHI has tracked the growth, challenges, and opportunities in this space; and on February 25 - 27, 2009, it will host the 16th International Molecular Medicine Tri-Conference in San Francisco, California.
CommerceNet’s own Dr. Jay M. Tenenbaum will give a plenary keynote on February 25 from 8:55 - 9:40am that focuses on “Therapy Development in a Network World.”
CommerceNet will be hosting its annual holiday party–complete with its traditional chocolate fountain–on Monday, December 15. Attendance is by invite only.
Want to attend? Contact Keren Wasserman for more information. All RSVPs are due by December 1.
CommerceNet Chairman and Founder Dr. Jay M. Tenenbaum attended the National Cancer Institute (NCI) Translational Science Meeting, November 7 - 9, 2008, at the Grand Hyatt Hotel in Washington, D.C.
This by-invitation-only event is designed to identify opportunities for accelerating the conversion of basic science discovery to the point of early state clinical trials using a poster discussion format.
Jeff Shrager, CTO at CollabRx, a CommerceNet portfolio company, participated in a panel titled “Pharma and Health 2.0″ at this year’s Health 2.0 Conference in San Francisco. During the session, Dr. Shrager demonstrated how the CollabRx e-science platform connects researchers to one another and to a network of scientific services.
Health 2.0: User-Generated Healthcare 2008
The San Francisco Marriott
October 22 - 23, 2008
Breakout Session D (October 23, 2008)
Pharma and Health 2.0
The PRISM Forum has an international membership of senior life science informaticians drawn from a number of biopharmaceutical organizations. The Forum meets twice a year, once in Europe and once in the USA, to exchange precompetitive information and to consider the application of emerging IT technologies within the biopharmaceutical research process.
Marty Tenenbaum, chairman and founder of CommerceNet and chairman and chief scientist of CollabRx (a CommerceNet Portfolio company), gave the keynote address at the PRISM special interest group on open innovation. His presentation focused on the structural problems in the existing drug development process and how open innovation and Health Commons can minimize them–making it affordable to develop treatments for rare and orphan diseases.
Abstract
Imagine a virtual marketplace or ecosystem where participants share data, knowledge, materials, and services to accelerate research. This Health Commons is a bold vision whose aim is no less than to change the processes, economics, and culture of translating basic research into drugs.
25+ million patients and their families suffer from over 6,000 orphan diseases that are currently uneconomical to address. The time is ripe for a radically different approach that leverages collaboration and the Internet to enable small teams of researchers to develop new therapies in a cost-effective manner and get them to patients quickly.
Virtual biotechs, using innovative research and clinical and business strategies, will exploit the Commons to slash the time and costs associated with drug development. As a result, a small group of patients with a rare disease can fund the development of new therapy in time to save their own lives. In the age of genomic sub-typing and personalized medicine–where every disease is potentially an orphan disease–the implications are far-reaching.
Jonathan Jacoby, COO at CollabRx, a CommerceNet portfolio company, participated in a panel discussion on “Organizational Structure, Leadership, and Financial Models” at an Institute of Medicine workshop titled “Venture Philanthropy Strategies Used by Patient Organizations to Support Translational Research.” The workshop took place on October 3, 2008, in Irvine, CA.
The panel: